US 12,115,138 B2
Tetrahydrocurcumin compositions, methods of making, and methods of using the same
Donald Jeffrey Keyser, Southlake, TX (US); Alvaro F. Guillem, Lantana, TX (US); Bhupinder Singh, Phoenix, AZ (US); and Richard A. Zager, Mercer Island, WA (US)
Assigned to RENIBUS THERAPEUTICS, INC., Southlake, TX (US)
Filed by RENIBUS THERAPEUTICS, INC., Southlake, TX (US)
Filed on Mar. 6, 2020, as Appl. No. 16/811,759.
Claims priority of provisional application 62/955,577, filed on Dec. 31, 2019.
Claims priority of provisional application 62/814,426, filed on Mar. 6, 2019.
Prior Publication US 2020/0281871 A1, Sep. 10, 2020
Prior Publication US 2021/0308074 A9, Oct. 7, 2021
Int. Cl. A61K 31/12 (2006.01); A61K 9/127 (2006.01); A61K 31/145 (2006.01); A61K 31/16 (2006.01); A61K 31/355 (2006.01); A61K 31/375 (2006.01); A61K 31/385 (2006.01); A61K 31/7048 (2006.01); A61K 47/10 (2017.01); A61K 47/24 (2006.01); A61K 47/34 (2017.01)
CPC A61K 31/12 (2013.01) [A61K 9/127 (2013.01); A61K 31/145 (2013.01); A61K 31/16 (2013.01); A61K 31/355 (2013.01); A61K 31/375 (2013.01); A61K 31/385 (2013.01); A61K 31/7048 (2013.01); A61K 47/10 (2013.01); A61K 47/24 (2013.01); A61K 47/34 (2013.01)] 17 Claims
OG exemplary drawing
 
1. A pharmaceutical composition comprising:
a) tetrahydrocurcumin (THCu) according to the formula:

OG Complex Work Unit Chemistry
and
b) a pharmaceutically acceptable excipient, wherein the pharmaceutical formulation lacks detectable amounts of hexahydrocurcumin (HHC) as indicated by no peak with a relative retention time of 7.14-7.15 while exhibiting a peak associated with THCu at 9.07 for THCu as determined by gas chromatography (GC).